Latest News
Neladalkib vs Lorlatinib: How GSK’s New ALK Drug Compares
Anyone searching neladalkib vs lorlatinib will find no head-to-head trial. No published evidence yet shows which drug is better. What the data do show is narrower. The US Food and Drug Administration (FDA) granted accelerated approval to neladalkib, branded Nelkarmi,...
Latest News
Ivonescimab FDA Approval: What the Complete Response Letter Means
The FDA has declined to approve ivonescimab for EGFR-mutated lung cancer, Summit Therapeutics said on Sunday 15 November 2026. The agency issued a complete response letter, so ivonescimab FDA approval is not in place in this setting. The goal date had been Saturday 14...
Environmental Cost of AI and ML in Life Science: Is It Bad for the Planet?
During a lab internship, I spent three months counting cells under a microscope. One slide at a time, one cell at a time. Today a trained model can do that counting in seconds, and that speed raises a question about the environmental cost of AI. That is the promise of...
Efficiency vs. Resilience: The Defining Life Sciences Battle of 2027
Tension is building in the life sciences industry as companies are asked to do more with less, while balancing efficiency and resilience. In the U.S., healthcare costs are rising faster than the economy, putting pressure on pricing and reimbursement [1]. Investors are...
Weekly News Roundup | 16 November 2026
Life science news 16 November 2026: the FDA approved Sunharbo, which it calls the first factor XIa inhibitor for stroke prevention. Sunharbo is approved with antiplatelet therapy after a recent ischaemic stroke. Imfinzi with enfortumab vedotin gained approval in...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Preservative-Free Is Not Risk-Free: The Microbiology Behind Safe Cosmetics
I have noticed that many shoppers want cosmetics without preservatives, so brands have launched preservative-free cosmetics and other “free-from” lines. The science of microbiology however stays the same. Any product that holds water and nutrients can feed microbes....
COMP360 Approval: When Could Compass’s Psilocybin Be Cleared?
No COMP360 approval date exists yet, but the timetable is short. Compass Pathways said its rolling new drug application (NDA) should finish “in the next two weeks”. It made the statement on 3 November 2026, in its third-quarter 2026 results release. The company...
What Happens After a Digital Mental Health Screening Result
A self-assessment can identify symptoms, but the value of mental health screening depends on what people understand, choose and can access after seeing the result. A person completes an online mental health questionnaire and receives a score suggesting that...
Rethinking Biologics Plants to Earn Attractive Returns
The rapid growth of biologics and other advanced therapeutic modalities is transforming pharmaceutical R&D and manufacturing. From monoclonal antibodies and oligonucleotides to cell and gene therapies, these products introduce a level of process complexity,...
BioMarin Fabry Deal: What Does It Get for $70 Million Upfront?
The BioMarin Fabry deal gives the US company exclusive worldwide rights, outside Korea, to an early-stage injectable enzyme therapy. BioMarin announced the licence on 29 October 2026 with GC Biopharma and Hanmi Pharm. The candidate is HM15421/GC1134A, also known as...
The Fifty-Year Chase: Where Noninvasive Glucose Monitoring Stands in 2026
For nearly half a century, one problem has raised more capital, had more publications, and experienced more failed product launches than almost any other in medical devices: noninvasive glucose monitoring, or measuring blood glucose without breaking the skin. More...
ObesityWeek 2026 Preview: The Data to Watch in Washington
ObesityWeek 2026 runs from 14 to 17 November in National Harbor, Maryland, just outside Washington. The meeting is The Obesity Society’s 44th annual gathering. Novo Nordisk arrives with 26 abstracts, including the first results from REDEFINE 9, its lower-dose...
Extracellular Vesicles in Neurology: Is Translation Outpacing Science?
Extracellular vesicles are attracting growing attention in neurology because they can carry proteins, lipids and nucleic acids between cells and may reflect aspects of the biological state of their cells of origin. Their potential applications include liquid-biopsy...
BBP-418 Approval: When Could BridgeBio’s First LGMD Drug Launch?
BBP-418 approval is due to be decided by the US Food and Drug Administration (FDA) by 27 November 2026. That is the target action date for BridgeBio’s oral treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). BioSpace reported on 2 November 2026 that...
When AI Writes Medical Device Requirements, What Does It Miss?
Artificial intelligence is making its way into nearly every stage of medical device development, including one of the most foundational activities: defining product requirements. With a well-structured prompt, AI-generated requirements, spanning user needs, software...
ULP Launches Founders’ Bench Award for Ophthalmology Innovation
University Lab Partners Launches Inaugural Founders’ Bench Award to Accelerate Ophthalmology Innovation Bausch + Lomb joins as founding corporate partner; UCI’s Gavin Herbert Eye Institute serves as academic partner University Lab Partners (ULP) today announced the...
The Weakest Link in Your Manuscript May Be the Image You Overlooked
Image duplication, one of the most common image integrity problems in published research, can result from an inadvertent mix-up during figure preparation, reuse that has not been clearly explained, or deliberate fabrication. A 2025 analysis of the Retraction Watch...
Preservative-Free Is Not Risk-Free: The Microbiology Behind Safe Cosmetics
I have noticed that many shoppers want cosmetics without preservatives, so brands have launched preservative-free cosmetics and other “free-from” lines. The science of microbiology however stays the same. Any product that holds water and nutrients can feed microbes....
COMP360 Approval: When Could Compass’s Psilocybin Be Cleared?
No COMP360 approval date exists yet, but the timetable is short. Compass Pathways said its rolling new drug application (NDA) should finish “in the next two weeks”. It made the statement on 3 November 2026, in its third-quarter 2026 results release. The company...
What Happens After a Digital Mental Health Screening Result
A self-assessment can identify symptoms, but the value of mental health screening depends on what people understand, choose and can access after seeing the result. A person completes an online mental health questionnaire and receives a score suggesting that...
Rethinking Biologics Plants to Earn Attractive Returns
The rapid growth of biologics and other advanced therapeutic modalities is transforming pharmaceutical R&D and manufacturing. From monoclonal antibodies and oligonucleotides to cell and gene therapies, these products introduce a level of process complexity,...
BioMarin Fabry Deal: What Does It Get for $70 Million Upfront?
The BioMarin Fabry deal gives the US company exclusive worldwide rights, outside Korea, to an early-stage injectable enzyme therapy. BioMarin announced the licence on 29 October 2026 with GC Biopharma and Hanmi Pharm. The candidate is HM15421/GC1134A, also known as...
The Fifty-Year Chase: Where Noninvasive Glucose Monitoring Stands in 2026
For nearly half a century, one problem has raised more capital, had more publications, and experienced more failed product launches than almost any other in medical devices: noninvasive glucose monitoring, or measuring blood glucose without breaking the skin. More...
ObesityWeek 2026 Preview: The Data to Watch in Washington
ObesityWeek 2026 runs from 14 to 17 November in National Harbor, Maryland, just outside Washington. The meeting is The Obesity Society’s 44th annual gathering. Novo Nordisk arrives with 26 abstracts, including the first results from REDEFINE 9, its lower-dose...
Extracellular Vesicles in Neurology: Is Translation Outpacing Science?
Extracellular vesicles are attracting growing attention in neurology because they can carry proteins, lipids and nucleic acids between cells and may reflect aspects of the biological state of their cells of origin. Their potential applications include liquid-biopsy...
BBP-418 Approval: When Could BridgeBio’s First LGMD Drug Launch?
BBP-418 approval is due to be decided by the US Food and Drug Administration (FDA) by 27 November 2026. That is the target action date for BridgeBio’s oral treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). BioSpace reported on 2 November 2026 that...
When AI Writes Medical Device Requirements, What Does It Miss?
Artificial intelligence is making its way into nearly every stage of medical device development, including one of the most foundational activities: defining product requirements. With a well-structured prompt, AI-generated requirements, spanning user needs, software...
ULP Launches Founders’ Bench Award for Ophthalmology Innovation
University Lab Partners Launches Inaugural Founders’ Bench Award to Accelerate Ophthalmology Innovation Bausch + Lomb joins as founding corporate partner; UCI’s Gavin Herbert Eye Institute serves as academic partner University Lab Partners (ULP) today announced the...
The Weakest Link in Your Manuscript May Be the Image You Overlooked
Image duplication, one of the most common image integrity problems in published research, can result from an inadvertent mix-up during figure preparation, reuse that has not been clearly explained, or deliberate fabrication. A 2025 analysis of the Retraction Watch...
Featured Articles
Further News
Weekly News Roundup | 2 November 2026
Life science news 2 November 2026: four approvals, three deals and a UK Budget investment package. Ferring has agreed to acquire Gameto in a deal worth up to $1.3825bn. The FDA granted accelerated approval to Voceryq for recurrent respiratory papillomatosis. The MHRA...
ESMO 2026: The Five Results That Could Change Cancer Treatment
ESMO 2026 closed in Madrid on 27 October after five days of practice-shaping data. The most closely watched results came in three Presidential Symposia, which carried twelve late-breaking phase 3 trials. Five of them stand out for their potential to change how...
What Are You Signing When the AI Wrote the Note?
Anyone who has finished an emergency shift knows the chart stack. The department is still loud, the next team has the board, and a column of unsigned notes waits on the workstation. You read each one, fix what's wrong, and sign. That signature has always meant...
Peptide Compounding Explained: What the HHS Six-Peptide Policy Allows
Peptide compounding in the United States has entered a new phase. The Department of Health and Human Services (HHS) will not act against compounders of six unapproved peptides, within strict conditions. The peptides are BPC-157, Epitalon, KPV, MOTS-c, Semax and...
Clinical Trial Results 30 October 2026
Clinical trial results 30 October 2026: head and neck cancer, small cell lung cancer, type 2 diabetes and breast cancer. Genmab’s petosemtamab plus pembrolizumab met both co-primary endpoints in first-line PD-L1-positive head and neck cancer. Amgen’s tarlatamab plus...
Retatrutide vs Ozempic: How Do They Compare in Diabetes?
Retatrutide vs Ozempic now has a head-to-head answer in type 2 diabetes. In an 80-week phase 3 trial, retatrutide lowered A1C by 2.2 percentage points, against 1.8 for Ozempic 2 mg. Body weight fell by 19.5 to 20.9 per cent on retatrutide and 9.4 per cent on Ozempic....
Weight Is Not Composition: What Surgeons See After GLP-1 Weight Loss
The GLP-1 era has given clinicians something they have wanted for decades: medications that produce weight loss approaching what was once possible only with surgery. Semaglutide and tirzepatide routinely deliver reductions of 15% to 20% of body weight in trials, and...
Ferring Gameto Acquisition: What Does Ferring Get From the Deal?
The Ferring Gameto acquisition would give Ferring Pharmaceuticals control of Fertilo, Gameto’s lead investigational fertility programme. Fertilo is derived from induced pluripotent stem cells and is designed to mature eggs outside the body. Ferring and Gameto...
What the Next Generation of GLP-1s Means for Pharmacists and Patients
GLP-1 receptor agonists (GLP-1 RAs) have reshaped the treatment of type 2 diabetes and obesity. But the next phase of GLP-1 therapy, and of incretin-based treatment more broadly, is likely to have implications that extend well beyond the approval of another...
Del-Desiran Next Steps: Will Novartis Continue After HARBOR?
Novartis has not yet said whether it will keep developing del-desiran, its drug for myotonic dystrophy type 1 (DM1). The del-desiran next steps depend on the full HARBOR dataset and on talks with regulators. On 27 October 2026, Novartis reported a USD 1.9 billion...
Interoperability Begins Where Data Exchange Ends
Standards and APIs can move information. True healthcare interoperability requires the governance, trust and workflow design that make the information usable. Healthcare has spent years treating interoperability as a problem of moving data. National exchange has...
Psychobiotics and Depression: Exploring the Gut–Brain Connection
Depression care continues to evolve as researchers explore why people respond differently to treatment. One area drawing attention is the relationship between the gut microbiome and the brain. Could psychobiotics, which target this connection, offer additional support...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.













